tiprankstipranks
Ani Pharmaceuticals (ANIP)
NASDAQ:ANIP
US Market
ANIP
ANI Pharmaceuticals
RESEARCH TOOLSreports

ANI Pharmaceuticals (ANIP) Stock Forecast & Price Target

354 Followers
See the Price Targets and Ratings of:

ANIP Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
ANI
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ANIP Stock 12 Month Forecast

Average Price Target

$116.25
▲(56.65% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for ANI Pharmaceuticals in the last 3 months. The average price target is $116.25 with a high forecast of $124.00 and a low forecast of $100.00. The average price target represents a 56.65% change from the last price of $74.21.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"60":"$60","125":"$125","76.25":"$76.3","92.5":"$92.5","108.75":"$108.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":124,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$124.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":116.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$116.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[60,76.25,92.5,108.75,125],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.22,78.9723076923077,82.72461538461539,86.47692307692307,90.22923076923077,93.98153846153846,97.73384615384616,101.48615384615385,105.23846153846154,108.99076923076923,112.74307692307693,116.49538461538461,120.24769230769232,{"y":124,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.22,78.37615384615384,81.5323076923077,84.68846153846154,87.84461538461538,91.00076923076924,94.15692307692308,97.31307692307692,100.46923076923076,103.62538461538462,106.78153846153846,109.93769230769232,113.09384615384616,{"y":116.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.22,77.12615384615384,79.0323076923077,80.93846153846154,82.84461538461538,84.75076923076924,86.65692307692308,88.56307692307692,90.46923076923076,92.37538461538462,94.28153846153846,96.18769230769232,98.09384615384616,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.69,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.175,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.47,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.94,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.22,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$124.00Average Price Target$116.25Lowest Price Target$100.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on ANIP
Faisal Khurshid
Jefferies
Jefferies
$120
Buy
61.70%
Upside
Reiterated
03/25/26
ANI Pharmaceuticals (ANIP) Receives a Rating Update from a Top Analyst
Barclays Analyst forecast on ANIP
Glen Santangelo
Barclays
Barclays
$100
Buy
34.75%
Upside
Reiterated
03/19/26
Barclays Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)
Guggenheim Analyst forecast on ANIP
Vamil Divan
Guggenheim
Guggenheim
$124
Buy
67.09%
Upside
Reiterated
03/16/26
Guggenheim Remains a Buy on ANI Pharmaceuticals (ANIP)
Truist Financial Analyst forecast on ANIP
Les Sulewski
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), ANI Pharmaceuticals (NASDAQ: ANIP) and ALX Oncology Holdings (NASDAQ: ALXO)
H.C. Wainwright Analyst forecast on ANIP
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$121
Buy
63.05%
Upside
Reiterated
02/27/26
H.C. Wainwright Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)
J.P. Morgan Analyst forecast on ANIP
Ekaterina Knyazkova
J.P. Morgan
J.P. Morgan
$95→$115
Buy
54.97%
Upside
Reiterated
09/24/25
Strong Growth Potential for ANI Pharmaceuticals Driven by Cortrophin Gel and Strategic Expansion
Piper Sandler Analyst forecast on ANIP
David Amsellem
Piper Sandler
Piper Sandler
$80→$94
Buy
26.67%
Upside
Reiterated
08/08/25
ANI Pharmaceuticals price target raised to $94 from $80 at Piper SandlerANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler
Raymond James Analyst forecast on ANIP
Gary Nachman
Raymond James
Raymond James
$64.66→$86
Buy
15.89%
Upside
Reiterated
06/20/25
Raymond James Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on ANIP
Faisal Khurshid
Jefferies
Jefferies
$120
Buy
61.70%
Upside
Reiterated
03/25/26
ANI Pharmaceuticals (ANIP) Receives a Rating Update from a Top Analyst
Barclays Analyst forecast on ANIP
Glen Santangelo
Barclays
Barclays
$100
Buy
34.75%
Upside
Reiterated
03/19/26
Barclays Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)
Guggenheim Analyst forecast on ANIP
Vamil Divan
Guggenheim
Guggenheim
$124
Buy
67.09%
Upside
Reiterated
03/16/26
Guggenheim Remains a Buy on ANI Pharmaceuticals (ANIP)
Truist Financial Analyst forecast on ANIP
Les Sulewski
Truist Financial
Truist Financial
―
Hold
―
Reiterated
03/02/26
Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN), ANI Pharmaceuticals (NASDAQ: ANIP) and ALX Oncology Holdings (NASDAQ: ALXO)
H.C. Wainwright Analyst forecast on ANIP
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$121
Buy
63.05%
Upside
Reiterated
02/27/26
H.C. Wainwright Keeps Their Buy Rating on ANI Pharmaceuticals (ANIP)
J.P. Morgan Analyst forecast on ANIP
Ekaterina Knyazkova
J.P. Morgan
J.P. Morgan
$95→$115
Buy
54.97%
Upside
Reiterated
09/24/25
Strong Growth Potential for ANI Pharmaceuticals Driven by Cortrophin Gel and Strategic Expansion
Piper Sandler Analyst forecast on ANIP
David Amsellem
Piper Sandler
Piper Sandler
$80→$94
Buy
26.67%
Upside
Reiterated
08/08/25
ANI Pharmaceuticals price target raised to $94 from $80 at Piper SandlerANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler
Raymond James Analyst forecast on ANIP
Gary Nachman
Raymond James
Raymond James
$64.66→$86
Buy
15.89%
Upside
Reiterated
06/20/25
Raymond James Sticks to Its Buy Rating for ANI Pharmaceuticals (ANIP)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ANI Pharmaceuticals

3 Months
xxx
Success Rate
6/8 ratings generated profit
75%
Average Return
+15.72%
reiterated a xxx
 rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +15.72% per trade.
1 Year
Faisal KhurshidJefferies
Success Rate
7/8 ratings generated profit
88%
Average Return
+15.14%
reiterated a buy rating 13 days ago
Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +15.14% per trade.
2 Years
xxx
Success Rate
7/8 ratings generated profit
88%
Average Return
+8.75%
reiterated a xxx
 rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +8.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANIP Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
0
0
0
1
3
Buy
10
5
11
20
20
Hold
10
8
9
28
29
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
13
20
49
52
In the current month, ANIP has received 23 Buy Ratings, 29 Hold Ratings, and 0 Sell Ratings. ANIP average Analyst price target in the past 3 months is 116.25.
Each month's total comprises the sum of three months' worth of ratings.

ANIP Financial Forecast

ANIP Earnings Forecast

Next quarter’s earnings estimate for ANIP is $1.45 with a range of $1.11 to $1.88. The previous quarter’s EPS was $2.33. ANIP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ANIP has Performed in-line its overall industry.
Next quarter’s earnings estimate for ANIP is $1.45 with a range of $1.11 to $1.88. The previous quarter’s EPS was $2.33. ANIP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ANIP has Performed in-line its overall industry.

ANIP Sales Forecast

Next quarter’s sales forecast for ANIP is $212.80M with a range of $196.40M to $241.70M. The previous quarter’s sales results were $247.06M. ANIP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ANIP has Performed in-line its overall industry.
Next quarter’s sales forecast for ANIP is $212.80M with a range of $196.40M to $241.70M. The previous quarter’s sales results were $247.06M. ANIP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ANIP has Performed in-line its overall industry.

ANIP Stock Forecast FAQ

What is ANIP’s average 12-month price target, according to analysts?
Based on analyst ratings, Ani Pharmaceuticals’s 12-month average price target is 116.25.
    What is ANIP’s upside potential, based on the analysts’ average price target?
    Ani Pharmaceuticals has 56.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ANIP a Buy, Sell or Hold?
          Ani Pharmaceuticals has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Ani Pharmaceuticals’s price target?
            The average price target for Ani Pharmaceuticals is 116.25. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $124.00 ,the lowest forecast is $100.00. The average price target represents 56.65% Increase from the current price of $74.21.
              What do analysts say about Ani Pharmaceuticals?
              Ani Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of ANIP?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.